The stock of Paratek Pharmaceuticals Inc (NASDAQ:PRTK) hit a new 52-week low and has $9.06 target or 12.00% below today’s $10.30 share price. The 7 months bearish chart indicates high risk for the $224.67 million company. The 1-year low was reported on Nov, 1 by Barchart.com. If the $9.06 price target is reached, the company will be worth $26.96M less.
The 52-week low event is an important milestone for every stock because it shows very negative momentum and is time when sellers come in. During such technical setups, fundamental investors usually stay away and are careful buying the stock. About 91,404 shares traded hands. Paratek Pharmaceuticals Inc (NASDAQ:PRTK) has declined 33.33% since March 30, 2016 and is downtrending. It has underperformed by 36.35% the S&P500.
Analysts await Paratek Pharmaceuticals Inc (NASDAQ:PRTK) to report earnings on November, 10. They expect $-1.34 EPS, down 0.75% or $0.01 from last year’s $-1.33 per share. After $-1.69 actual EPS reported by Paratek Pharmaceuticals Inc for the previous quarter, Wall Street now forecasts -20.71% EPS growth.
Paratek Pharmaceuticals Inc (NASDAQ:PRTK) Ratings Coverage
Out of 6 analysts covering Paratek Pharmaceuticals (NASDAQ:PRTK), 5 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 83% are positive. Paratek Pharmaceuticals has been the topic of 10 analyst reports since July 23, 2015 according to StockzIntelligence Inc. Ladenburg Thalmann maintained it with “Buy” rating and $52 target price in Friday, June 17 report. The firm has “Hold” rating by Zacks given on Saturday, August 22. H.C. Wainwright maintained Paratek Pharmaceuticals Inc (NASDAQ:PRTK) on Friday, June 17 with “Buy” rating. Gabelli initiated Paratek Pharmaceuticals Inc (NASDAQ:PRTK) on Thursday, July 23 with “Buy” rating. Leerink Swann reinitiated Paratek Pharmaceuticals Inc (NASDAQ:PRTK) on Thursday, October 27 with “Outperform” rating. The stock of Paratek Pharmaceuticals Inc (NASDAQ:PRTK) has “Sell” rating given on Friday, August 14 by Zacks. Zacks upgraded Paratek Pharmaceuticals Inc (NASDAQ:PRTK) on Wednesday, September 2 to “Hold” rating. The stock has “Outperform” rating given by Robert W. Baird on Friday, May 13. The firm has “Hold” rating by Zacks given on Saturday, August 8. The rating was upgraded by Zacks to “Hold” on Tuesday, September 22.
According to Zacks Investment Research, “Paratek Pharmaceuticals, Inc. is a biopharmaceutical company. The Company focuses on the discovery, development, and commercialization of therapeutics that treat infectious disease agents. The Company’s lead product candidate, omadacycline, is a tetracycline-derived antibiotic being developed for use as a first-line monotherapy for serious community-acquired bacterial infections where antibiotic resistance is of concern for treating physicians. Its second product candidate, WC 3035 is a tetracycline-derived compound designed for use in the treatment of acne and rosacea. Paratek Pharmaceuticals, Inc., formerly known as Transcept Pharmaceuticals, Inc., is based in United States.”
Insitutional Activity: The institutional sentiment increased to 5.42 in 2016 Q2. Its up 4.27, from 1.15 in 2016Q1. The ratio improved, as 5 funds sold all Paratek Pharmaceuticals Inc shares owned while 7 reduced positions. 28 funds bought stakes while 37 increased positions. They now own 29.25 million shares or 145.06% more from 11.93 million shares in 2016Q1.
Northern Trust Corp last reported 172,979 shares in the company. Moreover, Renaissance Technologies Ltd has 0% invested in Paratek Pharmaceuticals Inc (NASDAQ:PRTK) for 102,264 shares. Tiaa Cref Investment Limited Liability has 0% invested in the company for 48,462 shares. Deutsche Retail Bank Ag holds 95,180 shares or 0% of its portfolio. Great Point Prtnrs Limited Liability Company holds 0.12% or 29,266 shares in its portfolio. Moreover, Royal National Bank & Trust Of Canada has 0% invested in Paratek Pharmaceuticals Inc (NASDAQ:PRTK) for 166 shares. Tekla Capital Mngmt Ltd Llc has 762,581 shares for 0.43% of their US portfolio. Peregrine Asset Advisers Inc last reported 11,800 shares in the company. Broadfin Cap Limited Liability Com has 1.09% invested in the company for 803,332 shares. Blackrock Institutional Tru Communications Na holds 0% or 141,176 shares in its portfolio. Fny Managed Accounts Ltd Liability has 1,000 shares for 0% of their US portfolio. Nea Management Limited Company has 0.05% invested in the company for 66,245 shares. Wealthtrust, a Alabama-based fund reported 100 shares. Teacher Retirement Sys Of Texas has 0% invested in the company for 1,602 shares. Blackrock Advsrs Lc holds 0% of its portfolio in Paratek Pharmaceuticals Inc (NASDAQ:PRTK) for 5,257 shares.
More notable recent Paratek Pharmaceuticals Inc (NASDAQ:PRTK) news were published by: Finance.Yahoo.com which released: “Paratek Pharmaceuticals, Inc. to Host R&D Day on November 17, 2016” on October 26, 2016, also Marketwatch.com with their article: “/quotes/zigman/3870025/realtime” published on April 21, 2011, Globenewswire.com published: “Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK) to Ring The Nasdaq Stock Market …” on October 03, 2016. More interesting news about Paratek Pharmaceuticals Inc (NASDAQ:PRTK) were released by: Quotes.Wsj.com and their article: “News Paratek Pharmaceuticals Inc.PRTK” published on October 31, 2014 as well as Globenewswire.com‘s news article titled: “Paratek Pharmaceuticals Completes Merger With Transcept Pharmaceuticals” with publication date: October 30, 2014.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.